Laura, Thanks for the reply. Hmmm, I have to wonder, are you a doctor? I apologize for the difficulty in reading. As it was I ran out of characters and didn't get to finish my point so I will do that now. I also was writing it very quickly. The point was to bring up the theory that this class may be a better option to be used earlier in type 2 diabetics due to the fact that incretin mimetics have a better ability to preserve beta cell function, improve fatty liver disease, have impact on insulin resistance as well as reduce the uptake of glucagon and sugar production from the liver. They also improve insulin production and improve the release of insulin at the appropriate times. What I am saying is that by taking a drug that shows evidence of slowing the progression of the disease that normally over time gets worse and leads large and wide to increases in other health problems that cost more money this preventive measure may save more in the long run.
I also feel the need to correct you on a few other things you had mentioned.
1. Metformin does not promote weight loss as you stated, it simply has not been shown to promote weight gain.
2. Metformin is not a true insulin sensitizer. There is speculation that it may improve insulin resistance as a possible result of its effects on AMPD/GLUT4. Again this is more speculative and somewhat propaganda oriented vs. hard evidence supporting this. Also, it also has some evidence towards increasing metabolism but again benefit is generally limited due to weak efficacy.
3. Metformin's primary, known mechanism of action is to suppress the production of glucose from the liver. The other advertised benefits are largely debateable due to a solid lack of supporting studies and is speculative. Furthermore, as a whole Metformin, even if it does do the various other things that some advertising and literature suggest has an overall weak efficacy compared to most all diabetes drugs. This is why it is (by true experts) regarded as only effective in pre-diabetes or newly diagnosed.
4. You mentioned problems with gastrointestinal upset relating to incretin mimetics, specifically Victoza. Less than 5% of people taking Victoza during clinical trials reported gastrointestinal upset. Specifically with Victoza, if the dose is properly titrated from .6mg at the start of administration that 5% is reduced even further. Also what many people report as gastrointestinal upset actually is a feeling of fullness due to the slower gastric emptying which curbs hunger. This is usually temporary. Metformin however causes gastrointestinal upset in over 50% of patients including uncontrollable bowel movements in the form of diarrhea. I apologize for this rant but I am tired of Metformin being paraded around as the best drug for type 2 diabetes when if you look at the details it clearly isn't. At the very least there is strong argument against it. Yes, I know doctors love to use it when they can in patients at all times regardless of pre, newly diag. or having diab. for several years already. It is a lot of hype however. There is strong evidence that it has no effect at all in people that have been diabetic from 2 years and longer.
5. You comment that most insurance companies will not cover the Incretin Mimetics due to cost and that they require proof of failure on other meds first is not accurate. Many insurance companies will cover either Byetta or its newer version Bydureon as tier 2 meds and many times does not require a prior authorization. When Victoza came out Byetta moved to being a more widely covered drug as its price was lower. Bydureon is also covered by many plans as some companies prefer it to Byetta due to better patient compliance. Lower overall cost due to lack of additional needles and less side effects than its predecessor. Victoza, on some plans was available for less than a year and many did require a PA. I am running out of characters so I will finish on another reply.